Literature DB >> 22698943

Nanotechnology applied to overcome tumor drug resistance.

Zibin Gao1, Linan Zhang, Yongjun Sun.   

Abstract

Emerging multidrug resistance (MDR) to chemotherapy is a major obstacle in successfully treating malignant diseases. Nanotechnology provides an innovative and promising alternative strategy compared to conventional small molecule chemotherapeutics to circumvent MDR. This review focuses on recent literature examples of nanotechnology applications to overcome MDR. The advantages and limitations of various nanotechnologies are discussed as well as possible approaches to overcome the limitations. Developing a practical nanotechnology-based drug delivery system requires further studies of the tumor microenvironment, the mechanisms of MDR to chemotherapy, the optimal dosage regimen of anticancer drugs and/or siRNA, the transport kinetics of nanocarriers in tumor stroma and the pharmacokinetics of drug-loaded nanocarriers within MDR tumor cells.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22698943     DOI: 10.1016/j.jconrel.2012.05.051

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  51 in total

1.  Folate and TAT peptide co-modified liposomes exhibit receptor-dependent highly efficient intracellular transport of payload in vitro and in vivo.

Authors:  Yaqin Zhu; Liang Cheng; Lifang Cheng; Fazhen Huang; Qing Hu; Ling Li; Chenmin Tian; Lin Wei; Dawei Chen
Journal:  Pharm Res       Date:  2014-05-24       Impact factor: 4.200

2.  Tumor Targeting Synergistic Drug Delivery by Self-Assembled Hybrid Nanovesicles to Overcome Drug Resistance.

Authors:  Meng-Qing Gong; Cong Wu; Xiao-Yan He; Jing-Yi Zong; Jin-Long Wu; Ren-Xi Zhuo; Si-Xue Cheng
Journal:  Pharm Res       Date:  2016-10-13       Impact factor: 4.200

Review 3.  Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles.

Authors:  Chiranjeevi Peetla; Sivakumar Vijayaraghavalu; Vinod Labhasetwar
Journal:  Adv Drug Deliv Rev       Date:  2013-09-19       Impact factor: 15.470

4.  Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers.

Authors:  Zhengfeng Wang; Kun Zhao; Yingxuan Zhang; Xinxin Duan; Yongfu Zhao
Journal:  Pharm Res       Date:  2019-08-08       Impact factor: 4.200

5.  Folate Conjugated Hybrid Nanocarrier for Targeted Letrozole Delivery in Breast Cancer Treatment.

Authors:  Abbas Hemati Azandaryani; Soheila Kashanian; Katayoun Derakhshandeh
Journal:  Pharm Res       Date:  2017-11-06       Impact factor: 4.200

6.  A Smart Paclitaxel-Disulfiram Nanococrystals for Efficient MDR Reversal and Enhanced Apoptosis.

Authors:  Imran Shair Mohammad; Wei He; Lifang Yin
Journal:  Pharm Res       Date:  2018-02-27       Impact factor: 4.200

Review 7.  Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.

Authors:  Javed Ahmad; Sohail Akhter; Nigel H Greig; Mohammad Amjad Kamal; Patrick Midoux; Chantal Pichon
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 8.  Nanopreparations to overcome multidrug resistance in cancer.

Authors:  Niravkumar R Patel; Bhushan S Pattni; Abraham H Abouzeid; Vladimir P Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2013-08-23       Impact factor: 15.470

Review 9.  Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.

Authors:  Shizhu Chen; Keni Yang; Ruslan G Tuguntaev; Anbu Mozhi; Jinchao Zhang; Paul C Wang; Xing-Jie Liang
Journal:  Nanomedicine       Date:  2015-12-17       Impact factor: 5.307

10.  Co-delivery of cisplatin and siRNA through hybrid nanocarrier platform for masking resistance to chemotherapy in lung cancer.

Authors:  Vivek Patel; Rohan Lalani; Imran Vhora; Denish Bardoliwala; Akanksha Patel; Saikat Ghosh; Ambikanandan Misra
Journal:  Drug Deliv Transl Res       Date:  2020-11-11       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.